$CWNM .11 News out Crown Marketing Patents Appro

[b]$CWNM[/b] .11 News out Crown Marketing Patents Approved in Mexico

CHAPEL HILL, NC, Feb 20, 2013 (MARKETWIRE via COMTEX) -- Crown Marketing (OTCQB: CWNM) is pleased to announce that patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in Mexico.

Mexico's pharmaceutical industry faces unique challenges. According to an American Enterprise Institute study, Mexico's $15.5 billion market is plagued by counterfeit goods. Illicit activity in Mexico's pharmaceutical industry is estimated at roughly USD 1.9 billion per year -- with counterfeiting representing 81 percent of that illicit market. This is a situation where Crown believes its unique technology could have a significant impact.

In addition to protecting Crown's interest in Mexico's burgeoning market, Crown believes that its drug delivery device would significantly inhibit the ability to counterfeit medications due to its unique form and process of manufacture.

The intellectual property supporting the Controlled Drug Delivery Technology (CDDT) is comprehensively formulated to allow for the broad application of the technology with regard to the mode of administration, the desired release pattern, the type of compounds employed and the dosage form.

The technology can be employed to regulate time to first release of drug, the extent of the initial bolus release and the duration of the remaining controlled release. These programmable release profiles may be adjusted for considerations given to the different gastric and intestinal environments.

Crown's patent portfolio continues to increase as it is pursuing novel applications of its drug delivery technology.

About The Company:

Crown Marketing Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles diffusion through precise mathematical formulas. The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact:

Charles Van Der Ross

347-491-0565